Trial Profile
Effect of ombitasvir/ paritaprevir/ritonavir (ombitasvir/ABT-450/r) and dasabuvir with or without ribavirin (RBV) co-administered with raltegravir, rilpivirine, emtricitabine + tenofovir and efavirenz in healthy subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Oct 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir; Rilpivirine
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors AbbVie
- 27 Feb 2015 Status changed from not stated to completed.
- 17 Feb 2015 New trial record